Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 8464

Next Previous
Search
Drug Profile

CC 8464

Alternative Names: ASP-1807; CC-8464; CT-3000

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chromocell Corporation
  • Developer Channel Therapeutics Corporation
  • Class Analgesics; Antirheumatics
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Erythromelalgia; Neuropathic pain
  • Preclinical Postoperative pain
  • Research Ocular pain
  • Discontinued Diabetic neuropathies; Osteoarthritis; Sciatica

Most Recent Events

  • 11 Feb 2025 CC 8464 receives Fast Track designation for Erythromelalgia [PO] in USA (Chromocell pipeline, February 2025)
  • 11 Feb 2025 Chromocell plans a phase II trial for Neuropathic pain in fourth quarter of 2025 (Chromocell pipeline, February 2025)
  • 11 Feb 2025 Chromocell plans a phase III trial in fourth quarter of 2026 (Chromocell pipeline, February 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top